Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.43 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | FLT4 | P35916 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406531 | 0.79 | PTGS2 (0.49) | PTGS2PTGS1EGFRALKBH2ALKBH5 | |
| SCHEMBL10204163 | 0.79 | PTGS2 (0.55) | PTGS2PTGS1EGFRALKBH2ALKBH5 | |
| SCHEMBL6403465 | 0.77 | PTGS2 (0.56) | PTGS2PTGS1EGFRALKBH2ALKBH5 | |
| SCHEMBL10204166 | 0.77 | PTGS2 (0.55) | PTGS2PTGS1EGFRALKBH2ALKBH5 | |
| SCHEMBL3659963 | 0.75 | PTGS1 (0.44) | PTGS2PTGS1KDM4EL3MBTL1 | |
| SCHEMBL10204165 | 0.75 | PTGS2 (0.56) | PTGS2PTGS1EGFRALKBH2ALKBH5 | |
| SCHEMBL10204162 | 0.74 | NPC1 (0.63) | PTGS2PTGS1ALKBH2ALKBH5FTO | |
| SCHEMBL10182362 | 0.73 | PTGS2 (0.79) | PTGS2PTGS1EGFRALKBH2ALKBH5 | |
| SCHEMBL6415254 | 0.72 | PTGS2 (0.55) | PTGS2PTGS1EGFRALKBH2ALKBH5 | |
| SCHEMBL6400785 | 0.71 | PTGS2 (0.51) | PTGS2PTGS1EGFRALKBH2ALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023850-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023850-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2629614-B1 | NEMATOCIDAL SULFONAMIDES | DU PONT (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20130190172-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190172-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012054233-A1 | NEMATOCIDAL SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190172-A1 | NEMATOCIDAL SULFONAMIDES | QSOX1, ARSA, NOX1 | PTGS2 995/4885PTGS1 304/4885EGFR 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.